Sort   by:  
 Page size 
UnknownAssessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles.
Not available
S-EPMC10559539 | biostudies-literature
UnknownQuantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
Not available
S-EPMC5269700 | biostudies-literature
UnknownAnalysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature.
Not available
S-EPMC7583802 | biostudies-literature
UnknownEfficacy of vaccination therapy in newly diagnosed and recurrent glioblastoma patients: a meta-analysis.
Not available
S-EPMC12210592 | biostudies-literature
UnknownLow-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
Not available
S-EPMC5308696 | biostudies-literature
UnknownExtracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications.
Not available
S-EPMC8431127 | biostudies-literature
UnknownPrognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
Not available
S-EPMC9325931 | biostudies-literature
UnknownPhase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Not available
S-EPMC11819080 | biostudies-literature
UnknownQuantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomide.
Not available
S-EPMC11812022 | biostudies-literature
UnknownUndetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.
Not available
S-EPMC10589172 | biostudies-literature
Sort   by:  
 Page size